NASDAQ: GERN

Geron Corporation

Healthcare | Biotechnology

No licensed closing price on file for GERN. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

Geron Corporation (NASDAQ: GERN) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-21 13:08 UTC.

What Geron Corporation does

The company manufactures and sells RYTELO, a pharmaceutical product for myeloid hematologic malignancies. The drug's commercial success depends on acceptance by healthcare providers and patients, as well as coverage and reimbursement decisions made by government programs and insurance companies. RYTELO faces competition from established medications and therapies, and its adoption may be hindered by factors including clinical efficacy demonstrations, pricing, formulary inclusion, and prescriber and patient willingness to use the drug.

Summarized from Geron Corporation’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation	8-K 2026-05-27
Return on equity	-74.26%
Debt/equity	0.55

Revenue, margins & earnings

Net income
Taxes & interest
Operating costs
Net loss year

Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗

Recent Insider Activity (last 90 days)

Source: SEC EDGAR · Filed 2026-10-01

2026-10-01DirectorAward6,351$7.8K
2026-07-01DirectorAward6,103$7.8K
2026-05-26DirectorStock Option (right to buy)Award220,000—

Top Institutional Holders (latest 13F)

Source: SEC EDGAR · As of 2026-Q2

BlackRock, Inc.49,115,571$62.87M+3.8%
RA CAPITAL MANAGEMENT, L.P.42,809,751$54.80M-32.9%
Soleus Capital Management, L.P.42,808,659$54.80M+3.1%

View QoQ ownership changes →Full institutional ownership →

Recent 8-K Events (parsed from SEC filings)All events →

Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

2025-08-06Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2025-03-17Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2025-03-11Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →

Company news

View all →

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Yahoo2026-10-19
Geron Corporation Announces Oral Presentations Highlighting Imetelstat at International Hematology Congresses in Europe and Asia
Yahoo2026-10-12
Geron Q2 2026 Earnings Call: Complete Transcript
Benzinga2026-10-08
Did Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders?
prnewswire.com2026-09-25
Geron Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Geron Corporation - GERN
prnewswire.com2026-09-25NEG

Questions this page answers

What does Geron Corporation do?

The company manufactures and sells RYTELO, a pharmaceutical product for myeloid hematologic malignancies.

When did GERN last file with the SEC?

Geron Corporation's most recent SEC filing on record is a 8-K filed 2026-05-27. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-21 13:08 UTC. This page is also available as JSON at /api/data?ticker=GERN and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for GERN and 5,000+ tickers.

Create a free account — keep GERN

For your agent

GET /api/data?ticker=GERN

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt